HYDERABAD, India & LONDON–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/CRDO?src=hash" target="_blank"gt;#CRDOlt;/agt;–GVK BIO, a leading global Contract Research and Development Organisation
(CRDO), and LifeArc, one of UK’s top medical research charities, are
pleased to announce the 10th anniversary of a successful
partnership. The collaboration between LifeArc and GVK BIO brings
together two organizations with a singular vision: advancing novel
research ideas into potential medicines that can make a significant
difference to patients.
LifeArc’s novel approach involves levering partnerships with academia
and leading service organizations to advance discoveries into promising
medicines. Over the past decade, LifeArc scientific teams have focused
their efforts on modulating novel targets with therapeutic potential in
diseases where there is patient need, with the GVK BIO team assisting in
synthesizing complex molecules rapidly and cost effectively to drive
iterative improvement in efficacy and safety.
Promising novel chemical entities discovered from this partnership have
been either advanced by LifeArc into clinical development, or have been
licensed out to leading global pharmaceutical companies, including a
recently announced deal in neuroscience. As the partnership evolved from
a tactical relationship into a preferred partnership, the GVK BIO team
has augmented LifeArc’s internal biology efforts, by supporting
biochemical assays, carrying out drug metabolism and pharmacokinetics
profiling studies, and soon, will be developing cell-based assays and
running protein expression and purification studies.
“It has been our privilege to have collaborated with LifeArc and its
world class team of scientists that have delivered medicines such as
Keytruda®, Tysabri®, and Entyvio® among others,” said Manni
Kantipudi, Director & Chief Executive Officer, GVK BIO. “The
longevity of this partnership, and the transformative results of the
collaboration, serve as a testament to the capabilities of the GVK BIO
team and its commitment to work with customers to make a difference in
human life. We look forward to continuing this successful relationship
with LifeArc in the coming years.”
Commenting on the partnership, Melanie Lee, Chief Executive Officer,
LifeArc, said, “At LifeArc, we’re committed to translating
scientific innovation to benefit patients. Our partnership with GVK BIO
is a strong example of how shared goals and collaboration can create
real value.”
About GVK BIO
GVK BIO, a leading Contract Research & Development Organization
servicing the global Biopharma industry; is headquartered in Hyderabad,
India with operations in five sites including California, USA.
Established in 2001, GVK BIO has over 18 years of experience across the
Research and Development value chain with a focus on speed and quality
while ensuring safety and compliance. GVK BIO’s team of over 2100 highly
qualified scientists, backed by a no-conflict business model,
well-defined and scalable processes, modern facilities, and a strong
customer-centric partnering approach, focus on bringing its customers’
products to market. www.gvkbio.com
About LifeArc
LifeArc is a self-funded medical research charity. Our mission is to
advance translation of early science into health care treatments or
diagnostics that can be taken through to full development and made
available to patients. We’ve been doing this for more than 25 years and
our work has resulted in four licensed medicines and a diagnostic for
antibiotic resistance. Our success allows us to explore new approaches
to stimulate and fund translation. We have our own drug discovery and
diagnostics facilities, supported by experts in technology transfer and
intellectual property who also provide services to external clients. Our
model is built on collaboration, and we partner with a broad range of
groups including medical research charities, research organisations,
industry and scientists. www.lifearc.org
; Twitter @lifearc1
Contacts
Dorothy Paul
Dorothy.paul@gvkbio.com
+91 9908130236